Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Symptomatic case 9% Improvement Relative Risk Symptomatic case (b) 4% c19early.com/ex Saadeh et al. Exercise for COVID-19 Prophylaxis Favors exercise Favors inactivity
Saadeh, 587 patient exercise study: 9% fewer symptomatic cases [p=0.71] https://c19p.org/saadeh
copied to clipboard
Associations of pre-pandemic levels of physical function and physical activity with COVID-19-like symptoms during the outbreak
Saadeh et al., Aging Clinical and Experimental Research, doi:10.1007/s40520-021-02006-7
30 Oct 2021    Source   PDF   Share   Tweet
Retrospective 904 patients in Sweden, showing higher risk of COVID-19-like symptoms with poor muscle strength. Risk was slightly higher for physical inactivity, without statistical significance.
risk of symptomatic case, 9.1% lower, OR 0.91, p = 0.71, high activity levels 362, low activity levels 225, adjusted per study, inverted to make OR<1 favor high activity levels, 2+ symptoms, Table 8, physically active vs. inactive, multivariable, RR approximated with OR.
risk of symptomatic case, 3.8% lower, OR 0.96, p = 0.85, high activity levels 362, low activity levels 225, adjusted per study, inverted to make OR<1 favor high activity levels, 1+ symptoms, Table 2, model 2, physically active vs. inactive, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Saadeh et al., 30 Oct 2021, retrospective, Sweden, peer-reviewed, 6 authors, study period March 2020 - June 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperExerciseAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit